Even as other major market benchmarks struggled to stay in positive territory, the Nasdaq flirted with its record levels, climbing 1% as of 3 p.m. EDT.Biogen has asked the FDA to give the application priority review status in the hopes of becoming the first company to produce a therapy that can slow the health decline caused by Alzheimer's.